KIF23 antibody - N-terminal region (ARP33962_P050)
- Known as:
- KIF23 (anti-) - N-terminal region (ARP33962_P050)
- Catalog number:
- arp33962_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- KIF23 antibody - N-terminal region (ARP33962_P050)
Related genes to: KIF23 antibody - N-terminal region (ARP33962_P050)
- Gene:
- KIF23 NIH gene
- Name:
- kinesin family member 23
- Previous symbol:
- KNSL5
- Synonyms:
- MKLP1, MKLP-1
- Chromosome:
- 15q23
- Locus Type:
- gene with protein product
- Date approved:
- 1999-09-07
- Date modifiied:
- 2019-04-23
Related products to: KIF23 antibody - N-terminal region (ARP33962_P050)
Related articles to: KIF23 antibody - N-terminal region (ARP33962_P050)
- Kinesin family member 23 (KIF23) is a microtubule-dependent motor protein essential for cytokinesis, organelle transport, and signaling pathway regulation. Its dysregulation contributes to both tumorigenesis and non-malignant disorders; however, a comprehensive review integrating recent mechanistic and translational insights is currently lacking. - Source: PubMed
Publication date: 2026/05/24
Luo ChunmiaoQin FuxingYao DunweiMa QiucuiQin MinzhenLiew Fong Fong - Wilms tumor (WT) is a frequently diagnosed cancer in pediatric patients. DLX6-AS1 contributes to the emergence of several cancers. Nonetheless, the role of DLX6-AS1 in WT remains unclear. This study aimed to explore potential mechanisms by which DLX6-AS1 promotes the progression of WT. - Source: PubMed
Publication date: 2026/05/19
Chen JiaweiLi GuoweiChen LuqiuLi YunfengSun Fengyin - The pathogenic mechanisms underlying rheumatoid arthritis (RA) remain elusive. Lactylation, a novel post-translational modification, may regulate immune and metabolic reprogramming, underscoring the imperative to delineate lactylation-related genes (LRGs) driving RA progression. - Source: PubMed
Publication date: 2026/05/14
Hu XiaoliXiao QianWang LizhouXu YuanGou QiaoqiaoWen JingZhou Shi - Breast cancer (BC) is one of the most diagnosed malignancies and a leading cause of cancer-related mortality among women worldwide, thereby posing a substantial threat to women's health worldwide. However, clinically robust diagnostic biomarkers with high sensitivity and specificity, as well as well-validated molecular targets for targeted therapy, remain limited. - Source: PubMed
Publication date: 2026/03/30
Wang ZifuHou JinqiChen YiminLi JundiVengusamy Sivakumar - - Source: PubMed
Publication date: 2026/04/28
Zou Yuan-JingZhang Kun-HuanLu Ping-ShuangHou Yu-XuanLi Meng-XiangLiao Bi-YunZhao XinWang CaizhuSun Shao-Chen